<DOC>
	<DOCNO>NCT00537303</DOCNO>
	<brief_summary>This trial conduct Europe , Africa United States America ( USA ) . The aim trial compare safety efficacy two different insulin treatment , `` basic '' `` advance '' treatment type 2 diabetes .</brief_summary>
	<brief_title>Comparison Blood Sugar Lowering Effect Safety Two Insulin Treatments Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Type 2 diabetes mellitus 6 month HbA1c ( glycosylated haemoglobin A1c ) 7.5 % 10.0 % trial initiation ( screen ) BMI ( Body Mass Index ) less 40 kg/m2 Basal insulin treatment least 3 month ( NPH twice daily , insulin glargine detemir daily ) Treatment one 3 OADs Known suspect allergy trial product relate product Women pregnant , breastfeed intend become pregnant within next 48 week Previous participation trial include last 6 month Use 1 U/kg basal insulin daily trial initiation ( screen )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>